Chronic myeloid leukaemia (CML), also known as chronic myelogenous leukaemia, is a type of blood cancer that starts in the bone marrow’s blood-forming cells. Myeloid cells are immature cells capable of producing white blood cells, and when these cells continue to proliferate in an aberrant manner, it results in chronic myeloid leukaemia. Fatigue, fever, easy bleeding, infection, bone pain, anaemia, and swelling spleen are the most common symptoms of this malignancy in middle-aged and older individuals, while it can also affect children. CML is a slow-growing leukaemia that can transform into a fast-growing acute leukaemia that is more difficult to cure. The government’s continued support for the market by approving pipeline medications for CML is likely to drive growth. For example, in February 2014, Teva Pharmaceutical Industries Ltd.’s drug, SYNRIBO (omacetaxine mepesuccinate) for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) got the U.S. FDA approval.
Request for Analysis of COVID-19 Impact on Chronic Myeloid Leukemia Treatment Market –
The chronic myeloid leukaemia treatment market is expected to develop due to an increase in the number of studies being conducted to determine the causes of CML malignancy. TKIs (tyrosine-kinase inhibitors) are a type of targeted medicine that has been shown to improve long-term survival rates. Dasatinib (Sprycel) was also approved by the Food and Drug Administration (FDA) in 2017 for the treatment of chronic myeloid leukaemia in children. In order to discover medications that can operate on numerous targets, researchers are concentrating on polypharmacology. As a result, drug development prospects beyond the paradigm of “one medication, one target” are emerging. Because chronic myeloid leukaemia is more aggressive in children and teenagers, medication approval can aid in effective treatment.
Small molecule medicines have also become the cornerstone for first-line CML care, thanks to the introduction of imatinib and the second generation TKIs, dasatinib and nilotinib. However, the exorbitant cost of the pharmaceuticals used to treat this disease is a key stumbling block to the market’s expansion. TKI medications, for example, are quite expensive, hence generic pharmaceuticals are being launched in several nations. The market is expected to rise due to the rising prevalence of this cancer in various areas. For example, according to an article published in UBM Medica LLC, CML accounts for around 15% of the total leukemia cases in adults. Approximately 8,220 new cases of CML were diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.
The global chronic myeloid leukaemia market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa based on region. Because of the rising prevalence of chronic myelogenous leukaemia in developed countries due to genetic reasons, North America is likely to acquire substantial traction in the chronic myeloid leukaemia treatment market, followed by Europe. According to the American Cancer Society, approximately 8,430 new instances of CML will be diagnosed in 2018 (4,980 in men and 3,450 in women), with approximately 1,090 persons dying from the disease (620 men and 470 women). However, better healthcare infrastructure in rising economies such as China and India is assisting in the growth of the Asia Pacific chronic myeloid leukaemia treatment market.
Request PDF Brochure Report –
Tough rivalry among major manufacturers for market dominance in the CML market may create chances for innovative drug development and new strategies that take into account the mindset of end users. Since 2015, the bulk of big players’ medications for this illness have been approved. Bristol Meyer Squibb’s Sprycel (approved in December 2017), Novartis’ Gleevec and Tasigna (approved in March 2018), Takeda Pharmaceuticals’ Iclusig (authorised in 2018), and Pfizer’s Bosulif are examples of commercialised products (approved in December, 2017). Teva Pharmaceuticals Industries Ltd., Hoffman-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, Pfizer, Inc Hospira, Inc, Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, and Otsuka Pharmaceutical Co., Ltd are among the market players in the chronic myeloid leukaemia treatment market.
Chronic Myeloid Leukemia Treatment Market Taxonomy
By Drug Type
- Bosulif (Bosutinib)
- Gleevec (Imatinib)
- Iclusig (Ponatinib)
- Sprycel (Dasatinib)
- Tasigna (Nilotinib)
- Synribo (Omacetaxine Mepesuccinate)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Reasons to Purchase this Report
Current and future of global Chronic Myeloid Leukemia Treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Major Point Answered in Chronic Myeloid Leukemia Treatment Market Research Study are:
What will be the progress rate of the Chronic Myeloid Leukemia Treatment Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Chronic Myeloid Leukemia Treatment Market across different regions?
Who are the major vendors dominating the Chronic Myeloid Leukemia Treatment industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Chronic Myeloid Leukemia Treatment Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027